10-Q quarterly report · filed Nov 5, 2026

Dyne Therapeutics, Inc. (DYN) Q3 2026 10-Q Quarterly Report

Short answer

Dyne Therapeutics, Inc. (DYN) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$194M
−79.1% YoY · −8.4% QoQ
EPS (diluted)
−$1.08
−50.0% YoY · +0.0% QoQ

Source: XBRL data from the Dyne Therapeutics, Inc. (DYN) Q3 2026 10-Q on SEC EDGAR. USD.

Dyne Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no product sales since inception
  • Net loss $193.6M vs $108.0M YoY, operating margin not meaningful due to zero revenue
  • Best-performing program: z-rostudirsen R&D $66.9M vs $22.7M, worst: z-basivarsen $32.8M vs $37.9M
  • Cash, equivalents and marketable securities $1.134B; operating cash use $452.7M vs $291.4M YoY
  • July offering raised $404.9M; potential z-rostudirsen launch Q1 2027, cash runway into Q2 2028

Risk Factors

  • Newly added regulatory risk, BIOSECURE Act restrictions could disrupt Chinese supplier relationships and increase manufacturing costs
  • Most material update, DMD competition intensified after Avidity’s September 2026 priority review for delpacibart zotadirsen
  • Clinical risk, FDA previously placed z-rostudirsen’s IND on hold pending additional clinical and non-clinical information
  • Operational risk, reliance on single or limited suppliers for Fabs, linkers and payloads creates interruption exposure
  • Financial risk, $1.134 billion liquidity expected to fund operations through second quarter 2028, subject to plan assumptions

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Dyne Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.